Every 8-K that RAPHAEL PHARMACEUTICL INC (RAPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RAPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RAPH filings page.
Raphael Pharmaceutical Inc. (RAPH) entered into an Enterprise AI Transformation and Growth Partnership with AIcreatesAI Inc. effective July 30, 2026, under a one-year Annual Managed Services Agreement. AIcreatesAI will act as a managed partner for artificial intelligence transformation, commercialization, communications, product and growth operations.
The annual managed-services fee is $180,000, payable in monthly installments of $15,000, with automatic deferred payment obligations when funds are temporarily unavailable, remaining payable once Raphael receives financing, investment, commercial revenue or other resources. With AIcreatesAI’s written consent, deferred amounts may be satisfied with Raphael common shares, subject to securities laws and OTC Markets requirements. The Agreement also contemplates a Company-branded digital token platform, for which AIcreatesAI would receive 2% of net profits from the platform, separate from the service fee. Either party may terminate the Agreement for a material breach uncured for 15 days after written notice, and the parties remain independent contractors.
Raphael Pharmaceutical Inc. reports several senior leadership changes. Ajay Kumar Dhadha voluntarily resigned as Chairman of the Board and Director, effective June 30, 2026. The company states his resignation was not due to any disagreement regarding operations, policies, practices, financial reporting, management, or the Board.
Guy Ofir voluntarily resigned as Chief Financial Officer, General Counsel, and Director, effective July 16, 2026, also described as not resulting from any such disagreement. Effective July 16, 2026, Uri Tadelis was appointed as the company’s Chief Financial Officer.
Raphael Pharmaceutical Inc. reported a change in its Board of Directors. On December 31, 2025, the term of service of Dr. Yehuda Eliya as a board member expired, and he ceased to serve as a director as of that date. The company states that Dr. Eliya’s departure was not related to any disagreement with the company regarding its operations, policies, or practices, indicating a routine end-of-term transition rather than a conflict-driven resignation.